ClinicalTrials.gg
TerminatedNCT00127101Updated Apr 21, 2015Results posted

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)

A Phase 1 interventional study of vorinostat and Comparator: bexarotene in Lymphoma, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was stopped due to low enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing vorinostat in Lymphoma — none open to participants now, 1 under way, 1 of them phase 3. Vorinostat · Lymphoma.

Enrollment
7th of 19
23 · median 17
Started
2005
with 1 other
Phase 1
7 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
4 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing vorinostat in Lymphoma, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2005, is one of 7 in phase 1, and was the 2nd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

None of the 20 studies testing vorinostat in Lymphoma is open now. The open studies under Lymphoma, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing vorinostat in Lymphoma as a file.
02

Study summary

This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients who have failed at least one prior systemic therapy.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women or men greater than or equal to 18 years of age
  • Advanced cutaneous T-cell lymphoma, stage IB or higher including Sezary Syndrome with progressive, persistent, or recurrent disease
  • Failure of at least one systemic therapy, not including Bexarotene (Targretin)
  • (ECOG) status less than or equal to 2 (measurement to determine your ability to perform daily activities)

Exclusion criteria

Exclusion Criteria:

  • Patient has had treatment in the preceding 30 days
  • Active or C, history of
  • Prior treatment with any HDAC inhibitor
  • Patients must be disease free from prior for greater than 5 years, except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter\[2\] daily x 7 days per week

    Drug: vorinostat · Drug: Comparator: bexarotene

  • Experimental
    Cohort 2

    Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter\[2\] daily x 7 days per week

    Drug: vorinostat · Drug: Comparator: bexarotene

  • Experimental
    Cohort 2a

    Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter\[2\] daily x 7 days per week

    Drug: vorinostat · Drug: Comparator: bexarotene

  • Experimental
    Cohort 2b

    Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter\[2\] daily x 7 days per week

    Drug: vorinostat · Drug: Comparator: bexarotene

  • Experimental
    Cohort 6

    Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week

    Drug: vorinostat · Drug: Comparator: bexarotene

  • Experimental
    Cohort 7

    Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week \[150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)

    Drug: vorinostat · Drug: Comparator: bexarotene

Interventions

  • Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.

    Also known as: Zolinza

  • Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.

    Also known as: Targretin

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities

    Number of patients with Dose Limiting Toxicities (DLT). A DLT is an adverse event that determined the treatment dose level was not tolerable for that patient in Cycle 1.

    Time frame: Day 1 to day 28

Secondary outcomes

  1. Number of Participants Who Responded to Treatment

    Disease burden as assessed by the pre-specified Severity Weighted Assessment Tool (SWAT) measurement. A Response is defined as equal to or greater than 50% improvement in SWAT score. SWAT Score is determined by the Lesions classified as patch, plaque, or tumor. The sum of percent of total body surface area (%TBSA) by lesion type is derived and multiplied by a factor of 1 (for patch), 2 (for plaque), or 4 (for tumor). The skin score total is derived by summing the skin score subtotals for patches, plaques and tumors. The skin score total is dimensionless and can range from 0 to 400

    Time frame: Every 28 days for up to 6 Months of Treatment

07

Results

Posted Aug 14, 2009
Limitations and caveats
Study was discontinued due to low enrollment

Participant flow

Base Protocol
Participant flow — Base Protocol
MilestoneCohort 1Cohort 2Cohort 2aCohort 2bCohort 6Cohort 7
Started353354
Completed111333
Not completed242021
Withdrew: Adverse event021000
Withdrew: Lack of efficacy100020
Withdrew: Withdrawal by subject121001
Continuation Phase
Participant flow — Continuation Phase
MilestoneCohort 1Cohort 2Cohort 2aCohort 2bCohort 6Cohort 7
Started001033
Completed000000
Not completed001033
Withdrew: Adverse event000011
Withdrew: Lack of efficacy000001
Withdrew: Withdrawal by subject001021

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities

Number of patients with Dose Limiting Toxicities (DLT). A DLT is an adverse event that determined the treatment dose level was not tolerable for that patient in Cycle 1.

Time frame:
Day 1 to day 28
Reported as:
Number · Participants
Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities
ParticipantsCohort 1Cohort 2Cohort 2aCohort 2bCohort 6Cohort 7
DLT020001
No DLT333352
SecondaryNumber of Participants Who Responded to Treatment

Disease burden as assessed by the pre-specified Severity Weighted Assessment Tool (SWAT) measurement. A Response is defined as equal to or greater than 50% improvement in SWAT score. SWAT Score is determined by the Lesions classified as patch, plaque, or tumor. The sum of percent of total body surface area (%TBSA) by lesion type is derived and multiplied by a factor of 1 (for patch), 2 (for plaque), or 4 (for tumor). The skin score total is derived by summing the skin score subtotals for patches, plaques and tumors. The skin score total is dimensionless and can range from 0 to 400

Time frame:
Every 28 days for up to 6 Months of Treatment
Reported as:
Number · Participants
Number of Participants Who Responded to Treatment
ParticipantsCohort 1Cohort 2Cohort 2aCohort 2bCohort 6Cohort 7
Response000121
No Response353232

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1———
Cohort 2———
Cohort 2a———
Cohort 2b———
Cohort 6———
Cohort 7———
Most frequent serious events
Most frequent serious events
EventCohort 1Cohort 2Cohort 2aCohort 2bCohort 6Cohort 7
PyrexiaGeneral disorders0/30/51/30/30/50/4
Lymph Node AbscessInfections and infestations1/30/50/30/30/50/4
LymphangitisInfections and infestations1/30/50/30/30/50/4
T-Cell LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/50/30/30/50/4
Skin NecrosisSkin and subcutaneous tissue disorders0/30/51/30/30/50/4
GastroenteritisInfections and infestations0/30/50/30/30/51/4
HypersensitivityImmune system disorders0/31/50/30/30/50/4
PneumoniaInfections and infestations0/31/50/30/30/50/4
FallInjury, poisoning and procedural complications0/30/50/30/31/50/4
Mycosis FungoidesNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/50/30/31/50/4
Most frequent other events
Showing 10 of 127
Most frequent other events
EventCohort 1Cohort 2Cohort 2aCohort 2bCohort 6Cohort 7
FatigueGeneral disorders0/32/50/30/35/51/4
HypertriglyceridaemiaMetabolism and nutrition disorders3/33/52/31/31/52/4
HypothyroidismEndocrine disorders2/33/51/32/31/53/4
LeukopeniaBlood and lymphatic system disorders2/31/51/30/30/50/4
LymphopeniaBlood and lymphatic system disorders2/31/50/30/30/50/4
HypercholesterolaemiaMetabolism and nutrition disorders0/31/51/32/31/51/4
Muscle SpasmsMusculoskeletal and connective tissue disorders0/30/52/30/31/51/4
AnaemiaBlood and lymphatic system disorders0/33/50/30/30/50/4
DiarrhoeaGastrointestinal disorders0/33/50/30/31/51/4
NauseaGastrointestinal disorders0/31/50/30/33/52/4

Baseline characteristics

Age, Customized
Age, Customized(participants)Cohort 1Cohort 2Cohort 2aCohort 2bCohort 6Cohort 7Total
26-35 years of age0010102
36-45 years of age1100002
46-55 years of age0011114
56-65 years of age1112319
66-75 years of age1100024
Over 75 years of age0200002
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 2aCohort 2bCohort 6Cohort 7Total
Female2102229
Male14313214
Race/Ethnicity
Race/Ethnicity(participants)Cohort 1Cohort 2Cohort 2aCohort 2bCohort 6Cohort 7Total
Turkish0001001
White35325422
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Dummer R, Beyer M, Hymes K, Epping MT, Bernards R, Steinhoff M, Sterry W, Kerl H, Heath K, Ahern JD, Hardwick JS, Garcia-Vargas J, Baumann K, Rizvi S, Frankel SR, Whittaker SJ, Assaf C. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma. 2012 Aug;53(8):1501-8. doi: 10.3109/10428194.2012.656625. Epub 2012 Feb 13. PubMed 22239668 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2005
First posted
Aug 5, 2005
Start
Sep 2005
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Aug 14, 2009
Last update
Apr 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00127101
Responsible party
Sponsor
First posted
Aug 5, 2005
Start date
Sep 2005
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Aug 14, 2009
Last update
Apr 21, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion